Covid 19NCT05087355
Health Status Prior and Post Infection With Influenza or COVID 19: a Population Based Retrospective Analysis of 2016-2021
An observational study of Covid 19 and Influenza, run by Medical University of Vienna.
Trial summary
The overall project aim is to study outcomes after COVID-19 and influenza hospitalisation from 2016 - 2021 by retrieving data from the main social security carriers in Austria for the years 2010-2018 Read more about this study
- Who is it for?
- Any age
- What is being tested?
- PCR or antigen test for Covid 19 or Inluenza
- How many people
- 440,000 participants
- Where
- No sites listed yet
- Study dates
- 1 Jan 2016to 31 Aug 2021
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: All patients with or after Covid-19 or influenza between 2016-2021 in Austria will be included in this study
Who may be able to join
- Patients with SARS
- Patients with Covid-19
- Patients after Covid-19
- Patients with influenza
Who cannot join
- none
About this study
The overall project aim is to study outcomes after COVID-19 and influenza hospitalisation from 2016 - 2021 by retrieving data from the main social security carriers in Austria for the years 2010-2018
- Being tested
- PCR or antigen test for Covid 19 or Inluenza
- Medical subject headings
- COVID-19, Influenza, Human
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PCR or antigen test for Covid 19 or InluenzaDiagnostic test
PCR or antigen test for Covid 19 or Inluenza
| Study group | Role | What they receive |
|---|---|---|
| Influenza | Not described Receives: Diagnostic Test: PCR or antigen test for Covid 19 or Inluenza | |
| Covid 19 | Not described Receives: Diagnostic Test: PCR or antigen test for Covid 19 or Inluenza | |
| Control group | hospitalisation due to other disease (not influenza or Covid 19) Receives: Diagnostic Test: PCR or antigen test for Covid 19 or Inluenza |
What is being measured
The primary outcome is the main question the study is designed to answer.
Overall Mortality
Overall mortality after influenza or covid-19
Measured: 5 years
age distribution
age distribution in patients with influenza or covid-19
Measured: 5 years
risk profile
risk profile (e.g. prior diseases, medication) in patients who died due to influenza or covid-19
Measured: 5 years
newly diagnosed diseases
newly diagnosed diseases after influenza or covid-19
Measured: 5 years
newly prescribed medication
newly prescribed medication after influenza or covid-19
Measured: 5 years
duration of hospitalisation or unemployability
duration of hospitalisation or unemployability after influenza or covid-19
Measured: 5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Oct 2021
- Study start1 Jan 2016
- Primary completion31 Aug 2021
- Study completion31 Aug 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Covid 19Studies of the same condition, open and under way.
- More trials run by Medical University of ViennaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 440,000 participants (actual)
Sponsor and investigators
- Lead sponsor
- Medical University of Vienna
- Sponsor type
- University, hospital or other
- Collaborators
- Landesklinikum Sankt Polten, Sicknessfund Burgenland (BGKK), A.ö. Krankenhaus St. Josef Braunau GmbH
- Responsible party
- Principal investigator, Hendrik Jan Ankersmit, Medical University of Vienna
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05087355
- Sponsor's protocol ID
- AUTCOV-INFLU-STUDY
- Status last verified
- Oct 2021
- First submitted
- 19 Oct 2021
- Last updated
- 29 Oct 2021
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 29 Oct 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Health Status Prior and Post Infection With Influenza or COVID 19: a Population Based Retrospective Analysis of 2016-2021
- ClinicalTrials.gov ID
- NCT05087355
- Acronym / sponsor ID
- AUTCOV-INFLU-STUDY
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 440,000 participants (actual)
- Lead sponsor
- Medical University of ViennaUniversity, hospital or other
- Collaborators
- Landesklinikum Sankt Polten, Sicknessfund Burgenland (BGKK), A.ö. Krankenhaus St. Josef Braunau GmbH
- Study start
- 1 Jan 2016 (actual)
- Primary completion
- 31 Aug 2021 (actual)
- Study completion
- 31 Aug 2021 (actual)
- First posted
- 21 Oct 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The overall project aim is to study outcomes after COVID-19 and influenza hospitalisation from 2016 - 2021 by retrieving data from the main social security carriers in Austria for the years 2010-2018
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Influenza | – | Diagnostic Test: PCR or antigen test for Covid 19 or Inluenza |
| Covid 19 | – | Diagnostic Test: PCR or antigen test for Covid 19 or Inluenza |
| Control group | – | Diagnostic Test: PCR or antigen test for Covid 19 or Inluenzahospitalisation due to other disease (not influenza or Covid 19) |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- All patients with or after Covid-19 or influenza between 2016-2021 in Austria will be included in this study
Key inclusion criteria (4 listed)
- Patients with SARS
- Patients with Covid-19
- Patients after Covid-19
- Patients with influenza
Key exclusion criteria (1 listed)
- none
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PCR or antigen test for Covid 19 or InluenzaPCR or antigen test for Covid 19 or Inluenza | Diagnostic test | Control group, Covid 19, Influenza |
Primary outcome
Overall Mortality
Time frame: 5 years
Overall mortality after influenza or covid-19
age distribution
Time frame: 5 years
age distribution in patients with influenza or covid-19
risk profile
Time frame: 5 years
risk profile (e.g. prior diseases, medication) in patients who died due to influenza or covid-19
newly diagnosed diseases
Time frame: 5 years
newly diagnosed diseases after influenza or covid-19
newly prescribed medication
Time frame: 5 years
newly prescribed medication after influenza or covid-19
duration of hospitalisation or unemployability
Time frame: 5 years
duration of hospitalisation or unemployability after influenza or covid-19
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Oct 2021.
Related trials for Covid 19
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Active, not recruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19
Active, not recruiting
Intervention to Address Disparate Mental Health Consequences of COVID-19 Pandemic on Latinx and African Newcomers
Mental Health Issue, Mental Health Disorder
Recruiting
Home-Based Exercise Tele-Rehabilitation After COVID-19
Post SARS-CoV2 (COVID-19)
Not yet recruitingPhase 1
A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine
COVID -19
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
An observational study of Covid 19 and Influenza, run by Medical University of Vienna.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 29 Oct 2021. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Overall Mortality (time frame: 5 years). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Oct 2021.